R&D Strategies in securing funding for rare disease research An outline of emerging financing strategies for rare disease research in challenging times.
R&D Advanced manufacturing to pave way for pharma industry The time for transition to sustainable strategies is now.
R&D JP Morgan 2023 - Stefan Weber and Ravi Anand pharmaphorum sits down with Stefan Weber and Ravi Anand of neurology-focused biotech Newron.
Webinars Sponsored Medical Informatics and Rare Disease: a bridge between two w... With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th
R&D Rare Disease R&D: one step forward, but a long road ahead With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
